Honeywell has formed a collaboration with Bigfinite focused on delivering innovative solutions and platforms for the life sciences industry. The two companies will combine Honeywell’s expertise in process automation and controls technology with Bigfinite’s data analytics, artificial intelligence and machine learning platform, designed specifically for the biotechnology and pharmaceutical industries.
 
Honeywell’s life sciences-focused offerings, powered by the Bigfinite platform, will enhance manufacturing process operations and consolidate compliance-related manufacturing data contained in disparate systems across the enterprise into a single, visual interface for drug manufacturers. This will include data from laboratory information management, batch management, control, quality management, manufacturing execution and inventory systems. The goal is to enable more efficient audit-readiness and faster delivery of medical therapies to customers.
 
“The pharmaceutical industry is in deep transformation and the existing manual, labor-intensive tools are not up to par to handle this new reality,” said Pep Gubau, chief executive officer and co-founder, Bigfinite. “Honeywell, with Bigfinite’s platform, will accelerate the industry’s ability to tackle core operational challenges in entirely new ways.”
 
Together, Bigfinite’s cloud-based Software-as-a-Service (SaaS) platform and Honeywell’s advanced process automation and visualization provide real-time visibility and predictive insights through advanced analytics, artificial intelligence and Internet-of-Things (IoT) technologies with end-to-end data integrity. Through enhanced transparency, regulatory visibility and digital transformation of manual processes, the new solutions will allow life sciences companies to minimize regulatory risk, increase operational efficiencies and deliver products to customers faster while reducing rejections and waste of products.
 
“The Honeywell and Bigfinite collaboration underscores Honeywell’s enhanced focus on the life sciences industry,” said Cynthia Pussinen, vice president and general manager, Life Sciences and Specialty Chemicals, Honeywell Process Solutions. “It unlocks the potential to significantly impact the way in which life-saving medical therapies are delivered to patients around the world. The combined offering will provide an unprecedented view of adherence to compliance across the enterprise, ultimately improving the bottom line.”